A Phase 3 interventional study of SEP363856 and quetiapine XR in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 42 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.
Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 5th largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 3, and was the 10th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 3 · Phase 3 10
First in 2013; this study’s year is marked. 5 started in 2019.
This study's enrollment of 305 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 83 across the 23 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 3 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 34th largest by enrollment of the 111 interventional ones that give a count, is one of 13 that started in 2019, is one of 50 in phase 3, and was the 99th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing SEP-363856 in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.
This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.
This is a 52-week, multicenter, randomized, double-blind, parallel-group, flexible-dose study designed to evaluate the long-term safety and tolerability of SEP-363856 (50 to 100 mg/day) compared with quetiapine XR (400 to 800 mg/day) in clinically stable adult participants with schizophrenia. This study is projected to randomize a least 300 participants to two treatment groups (SEP-363856 50 to 100 mg/day or quetiapine XR 400 to 800 mg/day) in a 2:1 ratio. Study drug will be taken once a day and may be taken without food or with a light meal.
Sumitomo Pharma America Inc. was the former Sponsor and conducted this study. Sumitomo was responsible for analysis and clinical study report (CSR) completion. Otsuka took over study after IND was transferred and is concluding activities with registry postings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include, but are not limited to the following:
Exclusion criteria:
Main exclusion criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SEP363856 50mg, 75mg, 100mg, flexibly dosed once daily capsule
Drug: SEP363856
quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Drug: quetiapine XR
SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
Also known as: Seroquel XR
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first administration of study drug were considered AEs. A SAE is an AE that meets one or more criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.
Time frame: From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)
Participants took part in the study at investigational sites in Russia, US, Romania and Ukraine from 21 Nov 2019 to 30 Dec 2022.
| Milestone | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day |
|---|---|---|
| Started | 203 | 102 |
| Completed | 105 | 57 |
| Not completed | 98 | 45 |
| Withdrew: Randomized, but withdrawn from study prior to treatment | 2 | 0 |
| Withdrew: Withdrawal by participant | 17 | 9 |
| Withdrew: Geopolitical conflict related | 2 | 1 |
| Withdrew: Covid-19 related | 1 | 0 |
| Withdrew: Adverse event | 48 | 21 |
| Withdrew: Noncompliance with study drug | 5 | 1 |
| Withdrew: Lack of efficacy | 6 | 2 |
| Withdrew: Lost to follow-up | 6 | 7 |
| Withdrew: Protocol deviation | 5 | 1 |
| Withdrew: Participant relocated | 5 | 2 |
| Withdrew: Personal reasons | 0 | 1 |
| Withdrew: Deemed unsuitable for participation | 1 | 0 |
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Untoward medical occurrences that occured after first administration of study drug were considered AEs. A SAE is an AE that meets one or more criteria: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.
| Participants | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day |
|---|---|---|
| AEs | 153 | 77 |
| SAEs | 16 | 0 |
| AEs Leading to Trial Discontinuation | 48 | 21 |
Collected over From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SEP-363856 50 to 100 mg/Day | 0/201 (0%) | 16/201 (8%) | 103/201 (51.2%) |
| Quetiapine XR 400 to 800 mg/Day | 0/102 (0%) | 0/102 (0%) | 55/102 (53.9%) |
| Event | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day |
|---|---|---|
| SchizophreniaPsychiatric disorders | 10/201 | 0/102 |
| Suicide attemptPsychiatric disorders | 2/201 | 0/102 |
| Multiple injuriesInjury, poisoning and procedural complications | 2/201 | 0/102 |
| AnxietyPsychiatric disorders | 1/201 | 0/102 |
| Cerebrovascular accidentNervous system disorders | 1/201 | 0/102 |
| FallInjury, poisoning and procedural complications | 1/201 | 0/102 |
| Limb injuryInjury, poisoning and procedural complications | 1/201 | 0/102 |
| Corona virus infectionInfections and infestations | 1/201 | 0/102 |
| Event | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day |
|---|---|---|
| SomnolenceNervous system disorders | 12/201 | 21/102 |
| InsomniaPsychiatric disorders | 30/201 | 11/102 |
| AnxietyPsychiatric disorders | 27/201 | 10/102 |
| ConstipationGastrointestinal disorders | 7/201 | 12/102 |
| Weight increasedInvestigations | 9/201 | 11/102 |
| SchizophreniaPsychiatric disorders | 21/201 | 6/102 |
| HeadacheNervous system disorders | 20/201 | 8/102 |
| AstheniaGeneral disorders | 5/201 | 9/102 |
| DizzinessNervous system disorders | 16/201 | 5/102 |
| AkathisiaNervous system disorders | 14/201 | 2/102 |
Safety population included all participants that were enrolled and received at least 1 dose of study drug during the 52-week treatment period.
| Age, Continuous(years) | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day | Total |
|---|---|---|---|
| Mean | 40.3 ± 11.77 | 38.4 ± 12.66 | 39.7 ± 12.09 |
| Sex: Female, Male(Participants) | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day | Total |
|---|---|---|---|
| Female | 88 | 37 | 125 |
| Male | 113 | 65 | 178 |
| Ethnicity (NIH/OMB)(Participants) | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 12 |
| Not Hispanic or Latino | 193 | 98 | 291 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 47 | 28 | 75 |
| White | 150 | 73 | 223 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | SEP-363856 50 to 100 mg/Day | Quetiapine XR 400 to 800 mg/Day | Total |
|---|---|---|---|
| Romania | 2 | 1 | 3 |
| United States | 74 | 39 | 113 |
| Ukraine | 42 | 21 | 63 |
| Russia | 83 | 41 | 124 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Nov 2019 to primary completion in Dec 2022, 37 months.
Results were first posted in Dec 2025, 3 years after primary completion. A results delay was requested in Dec 2023.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 37 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc. →